KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Alnylam Pharmaceuticals (ALNY) Accumulated Depreciation & Amortization (2017 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Accumulated Depreciation & Amortization for 13 consecutive years, with $322.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 19.36% year-over-year to $322.7 million, compared with a TTM value of $322.7 million through Dec 2025, up 19.36%, and an annual FY2025 reading of $322.7 million, up 19.36% over the prior year.
  • Accumulated Depreciation & Amortization was $322.7 million for Q4 2025 at Alnylam Pharmaceuticals, up from $270.4 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $322.7 million in Q4 2025 and bottomed at $140.4 million in Q4 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $226.0 million, with a median of $223.1 million recorded in 2023.
  • The sharpest move saw Accumulated Depreciation & Amortization skyrocketed 34.57% in 2021, then increased 19.36% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $140.4 million in 2021, then grew by 23.53% to $173.4 million in 2022, then rose by 28.61% to $223.1 million in 2023, then increased by 21.2% to $270.4 million in 2024, then increased by 19.36% to $322.7 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for ALNY at $322.7 million in Q4 2025, $270.4 million in Q4 2024, and $223.1 million in Q4 2023.